Results 11 to 20 of about 11,732 (171)

Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only:Multicenter Propensity Score-matched Analysis [PDF]

, 2021
OBJECTIVE: This study compared median OS after resection of LAPC after upfront FOLFIRINOX versus a propensity-score matched cohort of LAPC patients treated with FOLFIRINOX-only (ie, without resection).
van Lienden, Krijn P, Magermans, Lisa G, van Eijck, Casper, de Hingh, Ignace H, Patijn, Gijs A, de Meijer, Vincent E, Brada, Lilly J H, Daamen, Lois A, van Santvoort, Hjalmar C, de Meijer, Vincent E; id_orcid, Koerkamp, Bas Groot, Festen, Sebastiaan, Wilmink, Hanneke J W, Walma, Marieke S, de Vries, Jan J J, Stommel, Martijn W J, Wessels, Frank J, Molenaar, Quintus I, Besselink, Marc G, Bruijnen, Rutger C, van Dam, Ronald M, Busch, Olivier R, Nio, Yung C, Latifi, Diba, Liem, Mike S L, Bosscha, Koop, Polée, Marco B   +26 more
core   +7 more sources

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions

Therapeutic Advances in Gastroenterology, 2017
Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine regimens were the preferred palliative first-line options for fit ...
Aurélien Lambert, Céline Gavoille, Thierry Conroy   +2 more
doaj   +2 more sources

Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma [PDF]

, 2021
Purpose: We investigated whether organoids can be generated from resected tumors of patients who received eight cycles of neoadjuvant FOLFIRINOX chemotherapy before surgery, and evaluated the sensitivity/resistance of these surviving cancer cells to ...
Farshadi, E.A., Land, F. van 't, Sampadi, B., Chang, J., Doukas, M., Vietsch, E.E., Pothof, J., Koerkamp, B.G., Sijde, F. van der, Eijck, C.H.J. van   +9 more
core   +4 more sources

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Case Reports in Oncology, 2020
Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment.
Garry Ceccon, Michael Wollring, Anna Brunn, Martina Deckert, Dirk Waldschmidt, Gereon R. Fink, Norbert Galldiks   +6 more
doaj   +1 more source

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

BMC Cancer, 2021
Background Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC).
Jiayuan Chen, Qingling Hua, Haihong Wang, Dejun Zhang, Lei Zhao, Dandan Yu, Guoliang Pi, Tao Zhang, Zhenyu Lin   +8 more
doaj   +1 more source

The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro

Scientific Reports, 2021
Cholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is ...
Olivia Jones, Xiaoqian Cheng, Saravana R. K. Murthy, Lawan Ly, Taisen Zhuang, Giacomo Basadonna, Michael Keidar, Jerome Canady   +7 more
doaj   +1 more source

Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients

healthbook TIMES. Oncology Hematology, 2021
Despite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at ...
Sara De Dosso, Alexander R. Siebenhüner, Thomas Winder, Alexander Meisel, Ralph Fritsch, Christoforos Astaras, Petr Szturz, Markus Borner   +7 more
doaj   +1 more source

Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy

Human Vaccines & Immunotherapeutics, 2021
The prognosis of patients with advanced pancreatic cancer is poor despite the recent introduction of immune checkpoint inhibitors. Therefore, the development of new therapeutic approaches is urgently required.
Shuichi Ota, Mamiko Miyashita, Yuka Yamagishi, Masahiro Ogasawara   +3 more
doaj   +1 more source

FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study) [PDF]

, 2022
香川大学Kagawa University博士（医学）Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer.
籏智, 幸政, Hatachi, Yukimasa, ハタチ, ユキマサ   +2 more
core  

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis

Scientific Reports, 2021
Treatment outcomes between FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and GNP (gemcitabine with albumin-bound paclitaxel) as first-line chemotherapy regimens for metastatic pancreatic cancer (PC) were assessed according to ...
Yoon Suk Lee, Jong-chan Lee, Jae-Hyeong Kim, Jaihwan Kim, Jin-Hyeok Hwang   +4 more
doaj   +1 more source